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ABSTRACT  
Background and aims: Depression and anxiety are commonly reported among patients in opioid main-
tenance treatment (OMT). The aim of the present study was to describe aspects of prescription of anti-
depresant drug therapy among patients on OMT. Our research questions were:  1) What is the prevalence 
of antidepressant use according to age and gender?  2) Which antidepressants are used?  3) How are anti-
depressants used in terms of reimbursement codes, dispensed dose and duration of therapy? 
Methods: Pharmacoepidemiological data were retrieved from the complete national Norwegian Prescription 
Database which contains information on all prescription drugs (such as Anatomical Theraputical Chemical 
(ATC)-code, Defined Daily Dose (DDDs)), dispensed at pharmacies to individual patients. Norwegian 
OMT-patients (N=4374, 3035 men and 1339 women) who received methadone mixture, buprenorphine 
capsules or combined buprenorphine-naloxone capsules for at least 6 months in 2009 were included. Pre-
valence of antidepressant use in the studied patients was measured in terms of retrieval of prescriptions. 
Results: During 2009 21.7% of the studied patients filled at least one prescription for an antidepressant 
drugs (men: 21.2%; women: 22.9%). The subgroup of antidepressants most frequently dispensed was 
selective serotonin reuptake inhibitors (SSRIs) (33%), followed by the sedative antidepressants mianserin 
and mirtazapin (22%) and tricyclic antidepressants (TCAs) (20%). Except for TCAs, prescriptions of all 
antidepressant subgroups were reimbursed for either anxiety or depression in 90% of the cases. Overall, 
46.9% of the antidepressant users were prescribed antidepressants in the category < 1 DDD per day and/or 
treatment < 3 months, with no gender difference. 
Conclusions: About one out of five OMT-patients filled a prescription for an antidepressant drug in 2009. 
Above 90% had their prescriptions reimbursed for either depression or anxiety. Use at low doses and/or 
sporadic use among half of the antidepressant users may reflect poor compliance or use for other maladies 
than the reimbursed disease code. Drug therapy for depression and anxiety among OMT-patients seems to 
be in line with recommendations for use; the SSRIs constitute the recommended drugs of choice due to 
their better effect/side effect profile, compared to the older antidepressants such as the TCAs. 
 
 
 
INTRODUCTION 
 
Depression is one of our most common psychiatric dis-
orders with an estimated 12 month prevalence of 7-10% 
of the adult population1,2. Among drug and alcohol abu-
sing individuals the prevalence rates are reported to be 
as high as 25-50%3,4. Prevalence rates of major depres-
sion among opiate-dependent patients enrolled in treat-
ment programs range between 10-30% in international 
studies5. This relatively large variation in prevalence 
may be explained by different study designs such as a 
varying length of participation in opioid maintenance 
(OMT)-programs at the time of diagnosis. Thus, depres-
sion and substance-dependencies commonly co-occur. 
This comorbidity has been associated with worse prog-
nosis, poorer treatment outcomes, and increased risk of 
suicide6-8. 
 OMT is the most common treatment for opiate ad-
diction in Europe9. In Norway there are approximately 
6000 patients in OMT10. A survey of Norwegian OMT 
patients in 2009 indicated an approximate prevalence 
rate of depressive symptoms of 16%, and about 20% 
had an anxiety disorder or symptoms that could point 
to this10. There were, however, large regional variat-
ions in the prevalence rates, e.g. for depression ranging 
from 7% in the county of Buskerud to 30% among 
OMT-patients in the county of Hedmark. These esti-
mates must be interpreted with great caution; informa-
tion was missing in 8% of the patients, and the results 
were not based on the use of clinically validated ques-
tionnaires. Still, it isn’t reasonable that the prevalence 
of depressive disorders in OMT patients should vary to 
this extent across the country. 
 According to data from the Norwegian Prescription 
Database (NorPD), 9.3% of all adult women and 5.0% 
of all men in Norway had at least one prescription of 
an antidepressant drug dispensed in 2004 and preva-
lence increased with age11. These figures resemble to a 
high degree the rates of depression in the population1,2. 
Antidepressants, however, are used also for several 
other conditions like anxiety disorders, eating disorder, 
pain management and to induce sleep. Thus, the preva-
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lence figures indicate that not all episodes of major 
depression are treated with antidepressants. 
 The pattern of antidepressant drug use in the general 
population is characterized by both an increasing use 
by age, and a higher level of use among women com-
pared to men. To our knowledge, there is limited infor-
mation on antidepressant drug therapy among patients 
enrolled in OMT-programs. Based on information from 
the nationwide NorPD, the aim of our study was to 
describe aspects of prescription of antidepressant drug 
therapy among patients on opioid maintenance therapy. 
 Our research questions were:  
1. What is the prevalence of antidepressant use accor-
ding to age and gender? 
2. Which antidepressants are used? 
3. How are antidepressants used in terms of reim-
bursement codes, dispensed dose (defined daily 
doses) and duration of therapy? 
 
 
MATERIAL AND METHODS 
 
Data source  
Data were drawn from the NorPD12. From January 1st 
2004, all pharmacies in Norway have been obliged by 
law to submit data electronically to the NorPD on all 
dispensed prescriptions. The NorPD contains informa-
tion on all prescription drugs, reimbursed or not, which 
are dispensed at pharmacies to individual patients 
outside institutions. Each record contains a unique 
person-identifier, which makes it possible to follow all 
prescriptions chronologically for each individual pa-
tient. Data on the prescribers are also collected, and 
each physician is identified by a unique identification 
code. Data on both patients and physicians are anony-
mized. Because data are collected from pharmacies, 
only prescribed drugs that are actually dispensed are 
captured in the NorPD. The data collected for our study 
were patients unique identifying number (encrypted), 
sex, age, the date of dispensing, and drug information 
(Anatomical Therapeutic Chemical (ATC)-code, 
Defined Daily Dose (DDDs)), and information on 
reimbursement codes. Reimbursement codes are wide 
categories of diseases, according to ICD-10 or ICPC 
coding, linking the prescribing to reimbursement. The 
following reimbursement codes were used: anxiety and 
depression: ICD code F3, F4 and ICPC code P73, P74, 
P76, P79, -74, -74, pain: ICD code -71, ICPC code      
-71, and other indications: ICD code -70. 
 All medicines dispensed in Norway are classified 
according to the ATC-classification system13. Quanti-
ties of dispensed drugs are measured in terms of the 
number of defined daily doses (DDDs). The basic defi-
nition of a DDD is the assumed average maintenance 
dose per day for a drug used for its main indication in 
adults13.The DDD for each drug is determined by the 
WHO collaborating centre for drug statistics13. See 
Table 1 for all antidepressant substances included in 
this study with assigned defined daily doses (DDDs). 
OMT in Norway  
The Norwegian OMT model was implemented during 
1998. To qualify for entry to the program, heroin users 
should have been dependent on heroin for several 
years and have had previous contact with abstinence-
oriented treatment. OMT has only been available 
through a public funded program run by specialized 
centers14. According to the National Directorate of 
Health 4900 patients were included in OMT programs 
in Norway by the end of 200815. Generally, OMT is 
provided as high-dose medication in Norway, and 
mean dosages for OMT medications in 2008 consti-
tuted 106 mg/day for methadone and 18 mg/day for 
buprenorphine16. 
 
Study population  
The study population was defined from retrieval of 
prescriptions of drugs used in OMT-programs during 
2009. Due to relatively high numbers of patients ente-
ring and leaving OMT programs each year, our study 
population were restricted to include patients on OMT 
for six months or longer only. It has been reported that 
most patients who quit OMT, quit within the first 
year17. 
 The study was based on prescription data from 
January 1st 2009 to December 31st 2009. Figure 1 
presents a flow chart of the study population, with 
inclusion and exclusion of patients. To be included in 
the study patients had to meet the following criteria: 
being dispensed either methadone mixture (ATC code 
N07BC02),  buprenorphine capsules (Subutex®; 
 
 
Table 1.  Antidepressant substances registered in Nor-
way in 2009, and included in the study, with assigned 
defined daily doses (DDDs). 
 
ATC code  Name  1 DDD 
Tricyclic antidepressants (TCAs) 
N06AA04   clomipramine  100 mg 
N06AA06   trimipramine  150 mg 
N06AA09   amitriptyline    75 mg 
N06AA10   nortriptyline    30 mg 
N06AA12   doxepin  100 mg 
Selective serotonin reuptake inhibitors (SSRIs) 
N06AB03  fluoxetine    20 mg 
N06AB04  citalopram    20 mg 
N06AB05  paroxetine    20 mg 
N06AB06  sertraline    50 mg 
N06AB08  fluvoxamine  100 mg 
N06AB10  escitalopram    10 mg 
Sedative antidepressants   
N06AX03  mianserin   60 mg 
N06AX11  mirtazepin   30 mg 
Others   
N06AG02  moclobemide  300 mg 
N06AX12  bupropion  300 mg 
N06AX16  venlafaxine  100 mg 
N06AX18  reboxetine      8 mg 
N06AX21  duloxetine    60 mg 
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Figure 1.  Flow chart of the study population, with 
inclusion and exclusion of patients. OMT = Opioid 
maintenance therapy. 
 
 
 
Table 2.  Characteristics of Norwegian patients in opioid 
maintenance therapy (OMT) more than six months in 2009 
according to age and type of therapy. 
 
  OMT-patients   
Study population, N 4374 
Men, n (%)  3035 (69.4) 
Age (mean, SD) 41.6 (SD 8.0) 
Methadone, n (%) 2489 (56.9) 
Buprenorphine, n (%) 1603 (36.6) 
Buprenorphine-naloxone combination; n (%)   819 (18.7) 
Two or more opioids*, n (%)   517 (11.8) 
*Patients who received two or more different opioids for 
maintenance therapy during the year. 
 
 
 
N07BC01) or buprenorphine-naloxone combined cap-
sules (Subuxone®; N07BC51) during the study period. 
Patients who had been dispensed methadone mixture 
with the reimbursement code for palliative treatment 
of malignant disease or methadone capsules were not 
included in the study. Patients who were dispensed 
tablets or capsules of methadone were excluded be-
cause these formulations of methadone are in Norway 
primarily used in pain therapy. Patients who died during 
2009 and patients who received opioid maintenance 
therapy for a short time (less than 6 months) were ex-
cluded from the study. 
 Patients who received their OMT-drug in specia-
lized centers and institutions during the study period 
were not available for inclusion in our study because 
their OMT drugs dispensed in institutions are not cap-
tured by NorPD. 
 
Antidepressants available in Norway  
In Norway antidepressants are available as prescription 
drugs only. Registered antidepressants in Norway were 
categorized into 4 groups: 1) selective serotonin reup-
take inhibitors (ATC code N06AB) 2) tricyclic anti-
depressants (N06AA) 3) sedative antidepressants; 
mianserin (N06AX03) and mirtazapin (N06AX11) and 
4) others. 
 
Analyses and statistics  
One-year prevalences of antidepressant use is presen-
ted and defined as retrieval of at least one prescription 
of an antidepressant dug during 2009. Distribution of 
antidepressant subgroups and reimbursement codes 
among antidepressant users in 2009 are presented as 
proportions. Further, the amount of antidepressant 
drugs dispensed (DDDs per day) was calculated as fol-
lows: Total DDDs dispensed in 2009 divided by (the 
number of days between last and first OMT drug dis-
pensed + number of DDDs at the last dispensed pre-
scription of antidepressant). Aspects of antidepressant 
use according to dispensed dose (DDDs) per day and 
duration of therapy were explored using the following 
four categories:  
> 1 DDD/day and treatment > 3 months 
> 1 DDD/day and treatment < 3 months 
< 1 DDD/day and treatment > 3 months 
< 1 DDD/day and treatment < 3 months  
The software SPSS 17.0 for Windows was applied for 
data management and descriptive statistics. 
 
 
RESULTS 
 
Study population  
4374 patients were included in the study, of whom 
69% were men (table 2). Overall, mean age was 41.6 
(SD 8.0) years and median age was 42 years, and the 
men were on average older than the women. More than 
half of the study population received methadone for 
opioid maintenance therapy, whereas the remaining 
patients received either buprenorhpine or buprenor-
hpine-naloxone in combination (no gender difference) 
(table 2).  
 
Prevalence of antidepressants dispensed to patients 
on OMT  
During 2009, 21.7% (949 out of 4374) of the study 
population filled at least one prescription for an anti-
depressant drug (men: 21.2%; women: 22.9%). Figure 
2 shows prevalences of antidepressant drug use by age. 
The highest prevalence of antidepressant use was ob-
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Figure 2.  Proportion of patients on opioid maintenance therapy who had at least one antidepressant 
drug dispensed in 2009, according to age. Percent. 
 
 
 
 
 
 
Figure 3.  Distribution of antidepressant subgroups among 
patients on opioid maintenance treatment who had at least 
one antidepressant drug dispensed in 2009. Percent. 
 
 
served among the youngest, aged 20-29 years, and 
oldest OMT patients, aged 60-69 years. 
 Figure 3 shows choice of antidepressant subgroups 
among OMT patients who had dispensed at least one 
prescription of antidepressant drug in 2009. The sub-
group of antidepressants most frequently dispensed was 
SSRI (33%), followed by the sedative antidepressants 
mianserin and mirtazapin (22%), TCA (20%), antide-
pressants in combination during the year (17%) and 
others (8%). A similar pattern of use was observed 
among men and women (figure 3). 
 
Antidepressants use according to reimbursement 
codes, dispensed dose and duration of therapy  
Table 3 shows antidepressant use according to reim-
bursements codes. Prescriptions of all antidepressant 
subgroups were reimbursed for either anxiety or de-
pression in 90% of the cases, except TCAs in which 
about three out of four of all prescriptions were 
reimbursed for for anxiety or depression (men: 74.6%, 
women: 76.1%). 
 Table 4 shows antidepressant use according to do-
ses per day and duration of treatment. Overall, 46.9% 
of the antidepressant users were prescribed antidepres-
sants in the category < 1 DDD per day and/or treat-
ment < 3 months. This was similar in both genders 
(men 46.7%; women 47.2%). Among TCA users, 92.6% 
of the patients were prescribed antidepressants at doses 
< 1 DDD per day and/or treatment < 3 months. 
 
 
DISCUSSION 
 
Overall; 22% of Norwegian OMT patients were on 
antidepressant drug therapy, in which about 90% were 
reimbursed for either depression or anxiety disorders. 
According to annual assessments of all OMT-centers 
in Norway in 2009, 16% of all OMT-patients had 
symptoms of depression, and about 20% had an 
anxiety disorder or symptoms that could point to this10. 
However, we do not know the extent to which these 
symptoms are overlapping in these patients. Thus, the 
present study cannot conclude on a divergence between 
the prevalence depression and anxiety morbidity and 
the drug treatment among OMT-patients. 
 Interestingly, approximately half of the antidepres-
sant drug users were prescribed drugs at low daily do-
ses (less than a DDD per day) or over a short period of 
time. These aspects of antidepressant drug use among 
OMT-patients could have several explanations. First, 
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Table 3.  Distribution of antidepressants according to reimbursement code among patients on opioid 
maintenance treatment in 2009. Number and percent. 
 
Reimbursement code  
depression/ 
anxiety pain other 
without reim- 
bursement code 
Men N (%) n (%) n (%) n (%) n (%) 
    SSRI*  208 (100) 200 (96.2) 0 1 (0.4)  8 (3.9) 
    TCA**  119 (100)   90 (75.6) 4 (3.4) 0  25 (21.0) 
    new sedative antidepressants 151 (100) 138 (91.4) 0 0 13 (8.6) 
    others    58 (100)   52 (89.7) 1 (1.7) 0    6 (10.3) 
    combinations 106 (100) 103 (97.2) 1 (0.9) 0  3 (2.8) 
Women      
    SSRI* 103 (100) 102 (99.0) 0 0  1 (1.0) 
    TCA**   71 (100)   54 (76.1) 4 (5.6) 0  13 (18.3) 
    new sedative antidepressants   61 (100)   56 (91.8) 0 0  5 (8.2) 
    others    21 (100)  21 (100) 1 (4.8) 0 0 
    combinations   51 (100)   50 (98.0) 4 (7.8) 0  1 (2.0) 
* SSRI- selective serotonin reuptake inhibitors  
** TCA- tricyclic antidepressants 
 
 
 
Table 4.  Distribution of antidepressants according to daily doses and duration of treatment among patients on opioid maintenance 
treatment in 2009. Number and percent. 
 
  
Use of 
antidepressants 
doses <1DDD/day 
and treatment 
<3 months 
doses >1DDD/day 
and treatment 
<3 months 
doses <1DDD/day 
and treatment 
>3 months 
doses >1DDD/day 
and treatment 
>3 months 
Men N (%) n (%) n (%) n (%) n (%) 
   SSRI* 208 (100) 0 21 (10.1) 34 (16.3) 153 (73.6) 
   TCA** 119 (100) 12 (10.1) 43 (36.1) 58 (48.7)   6 (5.0) 
   sedative antidepressants 151 (100) 5 (3.3) 39 (25.8) 26 (17.2)   81 (53.6) 
   others    58 (100) 2 (3.4) 15 (25.9)   9 (15.5)   32 (55.2) 
   antidepressants in combination 106 (100) 0 6 (5.7) 30 (28.3)   70 (66.0) 
Women      
   SSRI* 103 (100) 1 (1.0) 8 (7.8) 22 (21.4)   71 (69.9) 
   TCA**   71 (100) 3 (4.2) 28 (39.4) 32 (45.1)     8 (11.3) 
   sedative antidepressants   61 (100) 2 (3.3) 18 (29.5) 10 (16.4)   31 (50.8) 
   others    21 (100) 0   5 (23.8)   6 (28.6)   10 (47.6) 
   antidepressants in combination   51 (100) 0 3 (5.9)   7 (13.7)   41 (80.4) 
* SSRI- selective serotonin reuptake inhibitors  
** TCA- tricyclic antidepressants 
 
 
 
antidepressants may also be used at lower doses to 
alleviate sleep problems or as adjunctive therapy for 
pain. Even if more than 90% of the prescriptions were 
reimbursed for depression or anxiety disorders, we 
know from earlier observations that reimbursement 
(disease) codes that trigger reimbursement are used to 
help the patient, rather than being exact codes for the 
disease at hand. Thus the relatively high frequency use 
of low doses and/or more sporadic use may reflect use 
for other maladies than indicated by the reimburse-
ment code. Second, in addition to diagnosis, prescribed 
antidepressant drug dose depends on patients’ age and 
body weight, and treatment duration depends on thera-
peutic efficacy and adverse side effects, which all con-
stitute rational reasons for some patients to be prescri-
bed lower daily doses than a DDD per day and/or stop 
therapy. Third, poor compliance with prescribed anti-
depressant therapy may also contribute to patterns of 
sporadic retrieval of antidepressant drug prescriptions 
observed in this study. In this context, although pre-
scribed antidepressants may be dispensed, prescription 
data do not reveal any information on the extent to 
which the dispensed drugs actually are ingested. 
 Even though there is evidence that depression among 
opiate-dependent patients has been associated with 
worse prognosis, there is a debate on how to treat 
OMT-patients with concurrent depression. Firstly, stu-
dies of antidepressant drug therapy for depression 
during OMT have shown varied results18. A recent 
review concluded that there is mixed and possibly poor 
evidence supporting the clinical use of antidepressants 
for the treatment of depression in opioid addicts that 
are treated with opioid agonists19. It is not clear what 
accounts for the differences in response to anti-
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depressant drug therapy, and more research is needed 
to determine how to select opiate-dependent patients 
most likely to benefit from antidepressants. 
 Secondly, the debate concerns the complex relation-
ship between depression and opioid dependence. De-
pression may be a primary disorder, or may be secon-
dary to the toxic and withdrawal effects of drugs, or of 
psychosocial stress associated with addiction18,20. Entry 
into OMT-programs, and reduction of drug use, has in 
several studies been associated with improvement in 
depressive symptoms in many OMT-patients with 
major depression18,20. However, not all patients will 
have such a favorable response to entry into OMT-
programs. Our study population included OMT-
patients on long term stable OMT (6 months or lon-
ger), most likely belonging to the latter group. 
 Among the OMT-patients in our study SSRIs con-
stituted the antidepressant drug of choice. Only one 
out of five of the antidepressant users were prescribed 
TCAs, of whom about a quarter had their TCAs reim-
bursed for other indications than depression or anxiety. 
Further, only 5-10% of all TCA users had TCAs dis-
pensed at daily doses over a duration of time indicative 
of use for depression of anxiety, compared to 70% of 
all SSRI users. Thus, this observation may reflect that 
TCAs, when prescribed, probably mainly are used for 
other problems than anxiety or depression. A reason-
able conclusion from this may be that drug therapy for 
depression and anxiety among OMT-patients seems to 
be in line with recommendations for use; the SSRIs 
constitute the recommended drugs of choice due to 
their better effect/side effect profile, compared to the 
older antidepressants such as the TCAs. 
 Patterns of use of antidepressant drugs in the gene-
ral population in Norway is characterized by both an 
increasing use by age, and a higher level of use among 
women compared to men11. According to the NorPD, 
7.9% of all women and 4.2% of all men in Norway 
had at least one prescription of an antidepressant drug 
dispensed in 200912. Further, 4.1% of all 20-29 year 
olds had at least one prescription of an antidepressant 
drug dispensed in 2009, increasing to 9.6% of all 60-
69 year olds. Compared to the general population, a 
higher proportion of OMT-patients were dispensed 
antidepressants, with no gender difference, or an in-
creasing use by age. A higher level of use may be as 
expected, and in agreement with the higher prevalence 
of depression and anxiety (and other maladies) among 
OMT-patients compared to the general population. 
Similar level of use irrespective of age and gender 
among OMT-patients, may also reflect different pat-
terns of morbidity among OMT-patients compared to 
the general population. 
 The major strength of this study is that all dispensed 
drugs, both opioid maintenance drugs and antidepres-
sants are captured at an individual level, and that each 
individual can be followed over time with data on all 
dispensed drugs. On the other hand, as mentioned, 
there may be several limitations using information 
from NorPD as a datasource to describe patterns of 
drug use in the population; the dispensed drugs may 
not necessarily be consumed, the reimbursement code 
may not reflect the true reason for prescribing a drug, 
and the DDD may deviate from the actual prescribed 
daily dose. 
 In conclusion, about one out of five long-term 
OMT-patients had an antidepressant drug dispensed in 
2009, of whom above 90% had their prescriptions re-
imbursed for either depression or anxiety. Use at low 
daily doses and/or sporadic use among half of the 
antidepressant users may reflect poor compliance or 
use for other maladies than the reimbursed disease 
code. Drug therapy for depression and anxiety among 
OMT-patients seems to be in line with recommen-
dations for use; the SSRIs constitute the recommended 
drugs of choice due to their better effect/side effect 
profile, compared to the older antidepressants such as 
the TCAs. 
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